The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
Gregory Lawrence Beatty
No relevant relationships to disclose
Peter J. O'Dwyer
Research Funding - Incyte
Jason Clark
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jack G Shi
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Robert Charles Newton
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Richard Schaub
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Janet Maleski
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Thomas Gajewski
Research Funding - Incyte